mbiomics is a Munich-based techbio company building a platform to design, analyze, screen and manufacture defined, large microbial consortia as Live Biotherapeutic Products (LBPs). Its platform combines AI/ML-driven consortia design, proprietary analytical technology, large consortium co-cultivation, and screening capabilities to create pharmaceutical-grade, scalable microbiome therapeutics. The company is advancing a pipeline of indication-specific microbial communities intended to address patient heterogeneity across oncology and other diseases. Its lead candidate, MBX-116, is positioned as an immune checkpoint inhibitor co-therapy for second-line advanced melanoma, with a Phase 1B study planned for 2027. mbiomics is using recent Series A funding to build IND-enabling pharmacology data and accelerate GMP development and manufacturing as it moves into clinical execution. The company also plans to expand its pipeline into indications where the gut microbiome plays a central role, such as autoimmune and neurodegenerative diseases.

Total raised

$49M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2026